MARKET

PVLA

PVLA

Palvella Therapeutics Inc
NASDAQ
136.60
-3.09
-2.21%
After Hours: 133.96 -2.64 -1.93% 17:09 03/12 EDT
OPEN
136.56
PREV CLOSE
139.69
HIGH
136.95
LOW
131.37
VOLUME
173.12K
TURNOVER
--
52 WEEK HIGH
151.18
52 WEEK LOW
18.23
MARKET CAP
1.84B
P/E (TTM)
-35.6956
1D
5D
1M
3M
1Y
5Y
1D
Palvella Therapeutics launches ‘BEYOND mLM’ disease awareness campaign
TipRanks · 2d ago
PALVELLA THERAPEUTICS LAUNCHES "BEYOND MLM" DISEASE AWARENESS CAMPAIGN FOR MICROCYSTIC LYMPHATIC MALFORMATIONS IN COLLABORATION WITH LEADING LYMPHATIC, VASCULAR, AND DERMATOLOGY NONPROFIT ORGANIZATIONS
Reuters · 2d ago
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
Barchart · 2d ago
Weekly Report: what happened at PVLA last week (0302-0306)?
Weekly Report · 3d ago
Wednesday 3/4 Insider Buying Report: XRAY, PVLA
NASDAQ · 03/04 20:00
Palvella Therapeutics Director Elaine J Heron Acquires Common Shares
Reuters · 03/02 13:00
BTIG Remains a Buy on Palvella Therapeutics (PVLA)
TipRanks · 03/02 11:38
Weekly Report: what happened at PVLA last week (0223-0227)?
Weekly Report · 03/02 09:28
More
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Webull offers Palvella Therapeutics Inc stock information, including NASDAQ: PVLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PVLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PVLA stock methods without spending real money on the virtual paper trading platform.